b 29

Dynorphin B-29 (Leumorphin) (pig) is a peptide that exhibits multifaceted receptor interactions within the brain and isolated tissue systems. This compound is utilized in the study of immunoreactions [1].

MAO-B-IN-29 (compound 9a) acts as an inhibitor of MAO-B activity [1].

PTP1B-IN-29 (Compound A2B5) is a phosphatase inhibitor that targets protein tyrosine phosphatase 1B (PTP1B), TCPTP, and λPPase, with IC50 values of 1.27 μM, 4.38 μM, and 8.79 μM, respectively. PTP1B-IN-29 is applicable in the research of diabetes and obesity.

Compound 53, also known as HSD17B13-IN-29, is an inhibitor targeting hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC 50 ≤ 0.1 μM for estradiol. This compound is applicable in the study of liver, metabolic, and cardiovascular diseases, including NAFLD and NASH, and for investigating drug-induced liver injury (DILI) [1].

Anti-PD-L1/B7-H1 Antibody (29E.2A3) represents a chimeric antibody of mouse IgG2b, κ type, specifically targeting human PD-L1/B7-H1. The recommended isotype control for this antibody is Mouse IgG2b kappa, Isotype Control.

dopamine D3 receptor antagonist

NGB 2904 is a potent and selective antagonist of dopamine D3 receptor (Ki values are 1.4, 217, 223, 642, > 5000, > 10000 and > 10000 nM for D3, D2, 5-HT2, α1, D4, D1 and D5 receptors respectively). NGB2904 potently antagonizes mitogenesis stimulated by quinpirole (IC50 = 6.8 nM).

CB29 is a specific inhibitor of aldehyde dehydrogenase 3A1 (ALDH3A1).

Ulipristal acetate (CDB-2914) is an orally bioavailable selective progesterone receptor modulator with anti-progesterone activity. It binds to the progesterone receptor (PR), inhibiting PR-mediated gene expression and interfering with progesterone activity in the reproductive system, potentially suppressing the growth of uterine leiomyomatosis. Additionally, ulipristal can be used as emergency contraception by inhibiting or delaying ovulation and affecting endometrial tissue.

Ulipristal is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure.

UMB298 is a potent and selective CBP/P300 bromodomain inhibitor that inhibits BRD4 with an IC50 of 5193nM.

SB290157 trifluoroacetate is a potent and selective antagonist of the C3a receptor, with an IC50 of 200 nM.

TAB29 is a potent peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) inhibitor (IC50 of 874 nM), with therapeutic potential for human cancers.

Frovatriptan Succinate is a synthetic triptan with 5-HT1B/1D receptors agonist activity. It is indicated for the acute treatment of migraine.

Pamiparib is a highly potent and selective PARP inhibitor. BGB-290 selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, pro

SB297006 is an antagonist of C-C chemokine receptor 3 (CCR3; IC50 = 39 nM), which normally is activated by eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1δ. It is at least 250-fold selective for CCR3 over a panel of other chemokine receptors. SB 297006 blocks CCR3-mediated calcium mobilization induced by eotaxin, eotaxin-2, and MCP-4 in transfected cells. It suppresses antigen-induced accumulation of Th2 lymphocytes and eosinophils in lungs of mice when delivered subcutaneously (100 mg/kg).

Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor with IC50 values of 0.9 nM for PARP1 and 0.5 nM for PARP2. It exhibits strong PARP trapping, has the capability to penetrate the brain, and is used for researching various cancers, including solid tumors.

Pralurbactam is a β-Lactamase inhibitor utilized in the research of bacterial infections.

DB293 is an inhibitor of PIT-1 and BRN-3 transcription factors. DB293 binds as head-to-tail stacked dimers in the minor groove of 5'-ATGA sequence, thereby leading to an increase in the size of minor groove.

4-Fluorophenibut (developmental code name CGP-11130; also known as β-(4-fluorophenyl)-γ-aminobutyric acid or β-(4-fluorophenyl)-GABA) is a GABAB receptor agonist which was never marketed. It is selective for the GABAB receptor over the GABAA receptor (IC50 = 1.70 μM and > 100 μM, respectively). The drug is a GABA analogue and is closely related to baclofen (β-(4-chlorophenyl)-GABA), tolibut (β-(4-methylphenyl)-GABA), and phenibut (β-phenyl-GABA). It is less potent as a GABAB receptor agonist than baclofen but more potent than phenibut.

TQB-2928 is a monoclonal antibody targeting CD47, suitable for cancer research.

TQB2916 is a humanized IgG2 monoclonal antibody agonist that targets CD40. It exhibits significant antitumor activity by occupying CD40 and activating immune function. TQB2916 is applicable for research in advanced solid tumors and lymphomas.

AZD8797 (KAND567) is an orally available, selective and potent human CX3CR1-converting antagonist with inhibitory effects on CX3CR1 and CXCR2, and potentially protects against SARS-CoV-2-induced neuronal damage, preventing worsening of nociceptive sensitization and microglial activation in a migraine model of rats following seizures.

Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.